325 related articles for article (PubMed ID: 29728897)
1. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.
de Vries Schultink AHM; Bol K; Doornbos RP; Murat A; Wasserman E; Dorlo TPC; Schellens JHM; Beijnen JH; Huitema ADR
Clin Pharmacokinet; 2020 Jul; 59(7):875-884. PubMed ID: 32006223
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
5. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
6. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
[TBL] [Abstract][Full Text] [Related]
7. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
[TBL] [Abstract][Full Text] [Related]
9. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody.
Xue J; Kong D; Yao Y; Yang L; Yao Q; Zhu Y; Ding Y; Yang F; Gong J; Shen L; Zhou T
J Pharm Sci; 2020 Oct; 109(10):3172-3180. PubMed ID: 32565357
[TBL] [Abstract][Full Text] [Related]
11. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
12. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
13. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
Cancer Chemother Pharmacol; 2017 Mar; 79(3):545-558. PubMed ID: 28243682
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
[TBL] [Abstract][Full Text] [Related]
16. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and translational pharmacokinetics of a novel THIOMABâ„¢ antibody-antibiotic conjugate against
Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
[TBL] [Abstract][Full Text] [Related]
18. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
19. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
20. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]